Takeda releases additional Phase 3 data to bolster its orexin program amid new competition
read at Endpoints ↗Positive readoutPositive
Takeda announced new results from its two Phase 3 trials of an orexin‑targeting therapy.
The data are intended to demonstrate the drug’s efficacy and safety, reinforcing Takeda’s claim of market‑leading potential in the orexin space.
The announcement comes as another major player prepares to launch its own orexin development program, intensifying competition.
source
This writeup was produced by pharmadog from original reporting by Endpoints. The original article may no longer be reachable at its published URL.
Original headline: “Takeda fortifies orexin potential with more Phase 3 data”
read at Endpoints ↗
comments(0)
5-min edit window · permanent after that